Founded in 2008, MedAlliance is a privately-owned medical technology company. It is headquartered in Switzerland, with facilities in Irvine CA, Glasgow UK and Singapore.
MedAlliance specializes in the development of ground-breaking technology and commercialisation of advanced drug device combination products for the treatment of coronary and peripheral artery disease.
SELUTION SLR™ – Sustained Limus Release …a better choice for potential Drug-Eluting Balloon indications.
Using breakthrough proprietary technology, MedAlliance has found a solution to the challenge of controlled and sustained sirolimus release with SELUTION SLR™, a sustained limus release drug-eluting balloon catheter, for the treatment of both coronary and peripheral artery disease.
MedAlliance is the first and only company able to deliver the antiproliferative drug sirolimus in a drug-eluting balloon (DEB) with a sustained release profile similar to that of a drug-eluting stent (DES).
In February 2019 MedAlliance was granted Breakthrough Device Designation from the US Food and Drug Administration (FDA) for SELUTION SLR™. MedAlliance is honored to have been selected for the FDA’s Breakthrough Device Program, which will allow US patients timely access to new technologies with the potential to provide safer and more effective treatment.